|Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
Basic Trial Information
Further Trial Information
Trial Contact Information
Basic Trial Information
|Phase II||Treatment||Completed||18 and over||NCI-2009-00063|
MC0476, CDR0000433150, MAYO-MC0476, 6482, NCI-6482, JHOC-JS0652, JHOC-B/06/174, NCT00118248
This phase II trial is studying how well tanespimycin works in treating patients with inoperable locoregionally advanced or metastatic thyroid cancer. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing
Further Study Information
Analyses are performed separately for the cohort of patients with Medullary Thyroid Cancer and the cohort of patients with Differentiated Thyroid Cancer.
I. For each patient group, to estimate the proportion of patients who have not progressed or discontinue treatment within one year of starting tanespimycin (17AAG).
I. Determine the toxicity of this drug in these patients. Determine the 1-year progression-free rate in patients treated with this drug.
II. Determine the response rate and duration of response in patients treated with this drug.
III. Determine the time to treatment failure and time to subsequent therapy in patients treated with this drug.
IV. Determine the time to disease progression and overall survival of patients treated with this drug.
V. Correlate the incidence rate of RAS, RAF, and RET mutations with clinical outcome in patients treated with this drug.
OUTLINE: Patients receive tanespimycin intravenously (IV) over 2-6 hours on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After discontinuation of study treatment,
- patients who have not progressed on treatment are followed every 3 months until disease progression and then every 6 months for up to 3 years from study entry.
- patients who have progressed on treatment are followed every 6 months for up to 3 years from study entry.
- Diagnosis of thyroid carcinoma of 1 of the following types:
- Iodine I 131-resistant disease, defined as failure to incorporate and/or progression of measurable disease after treatment with iodine I 131
- Inoperable locoregionally advanced or metastatic disease
- Measurable disease, defined as ≥ 1 lesion ≥ 2.0 cm by conventional techniques OR ≥ 1.0 cm by spiral CT scan
- No active central nervous system (CNS) metastases
- Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)
- Aspartate aminotransferase (AST) ≤ 1.5 times ULN
- Creatinine ≤ 1.5 times ULN
- Corrected QT interval (QTc) < 450 msec for male patients (470 msec for female patients)
- Left ventricular ejection fraction (LVEF) > 40% by multiple gated acquisition scan (MUGA)
- diffusion capacity of lung for carbon monoxide (DLCO) ≥ 80%
- No cardiac symptoms ≥ grade 2
- No active ischemic heart disease within the past year
- No congenital long QT syndrome
- No left bundle branch block
- No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
- No myocardial infarction within the past year
- No New York Heart Association class III or IV congestive heart failure
- No poorly controlled angina
- No history of angina (of any sort) within the past 6 months
- No history of uncontrolled dysrhythmias or requiring antiarrhythmic drugs
- No history of cardiac toxicity after treatment with anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine)
- No other significant cardiac disease
- No uncontrolled infection
- No history of serious allergic reaction to eggs
- No pulmonary symptoms ≥ grade 2
- No symptomatic pulmonary disease requiring medication including the following:
- Dyspnea on or off exertion
- Paroxysmal nocturnal dyspnea
- Significant pulmonary disease (e.g., chronic obstructive/restrictive pulmonary disease)
- No home oxygen need meeting the Medicare criteria
- No history of pulmonary toxicity after treatment with anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine)
- Fertile patients must use effective contraception
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or noninvasive carcinoma
- No active seizure disorder
- More than 4 weeks since prior and no concurrent immunotherapy
- More than 4 weeks since prior biologic therapy
- No concurrent routine or prophylactic colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])
- More than 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered
- No other concurrent chemotherapy
- See Disease Characteristics
- More than 4 weeks since prior and no concurrent radiotherapy
- More than 4 weeks since prior radiopharmaceuticals
- No prior radiotherapy to > 25% of bone marrow
- No prior radiotherapy that potentially included the heart in the field (i.e., mantle) or chest
- More than 4 weeks since prior therapeutic surgery for the tumor
- More than 3 months since prior sublingual nitroglycerin
- No other concurrent investigational ancillary therapy
- Concurrent cytochrome P450 3A4 (CYP3A4) inhibitors allowed
- No concurrent medications that prolong or may prolong QTc interval
Trial Contact Information
Trial Lead Organizations/Sponsors
National Cancer Institute
|Jeffrey Moley||Principal Investigator|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00118248
ClinicalTrials.gov processed this data on September 29, 2014
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.